Price T Rowe Associates Inc Agenus Inc Transaction History

Price T Rowe Associates Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.63 - $1.14 $5,582 - $10,101	8,861 Added 3.92%	234,857 $195,000
Q3 2023 Nov 14, 2023	BUY	$1.12 - $1.88 $32,390 - $54,369	28,920 Added 14.67%	225,996 $256,000
Q2 2023 Aug 14, 2023	BUY	$1.31 - $2.04 $18,071 - $28,141	13,795 Added 7.53%	197,076 $316,000
Q1 2023 May 15, 2023	SELL	$1.45 - $2.95 $11,031 - $22,443	-7,608 Reduced 3.99%	183,281 $279,000
Q4 2022 Feb 14, 2023	BUY	$2.02 - $3.25 $14,927 - $24,017	7,390 Added 4.03%	190,889 $458,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.14 $40,033 - $64,134	20,425 Added 12.52%	183,499 $377,000
Q2 2022 Aug 15, 2022	BUY	$1.3 - $2.64 $37,758 - $76,678	29,045 Added 21.67%	163,074 $316,000
Q1 2022 May 16, 2022	BUY	$2.35 - $3.47 $29,896 - $44,145	12,722 Added 10.49%	134,029 $330,000
Q4 2021 Feb 14, 2022	BUY	$2.92 - $5.74 $224,031 - $440,390	76,723 Added 172.09%	121,307 $391,000
Q3 2021 Nov 15, 2021	SELL	$4.98 - $6.63 $498 - $663	-100 Reduced 0.22%	44,584 $234,000
Q2 2021 Aug 16, 2021	BUY	$2.56 - $5.49 $16,404 - $35,179	6,408 Added 16.74%	44,684 $245,000
Q1 2021 May 17, 2021	BUY	$2.69 - $5.25 $1,689 - $3,297	628 Added 1.67%	38,276 $104,000
Q4 2020 Feb 16, 2021	BUY	$3.17 - $4.49 $119,344 - $169,039	37,648 New	37,648 $120,000

2.07M

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.